🇺🇸 FDA
Pipeline program

Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

TV48125-CNS-30084

Phase 3 small_molecule active

Quick answer

Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen for Episodic and Chronic Migraine is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Episodic and Chronic Migraine
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials